TCF3

Across TCGA pan-cancer cohorts, TCF3 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TCF3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TCF3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TCF3 is over-expressed in tumor.

HNSC, BLCA, and COAD are the cancer types where TCF3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCF3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.650	<.001	12	view →
BLCA	All	III,IV	+1.359	<.001	11	view →
COAD	All	IV	+1.327	<.001	11	view →
KIRP	All	III,IV	+1.027	<.001	11	view →
LIHC	Female	II,III,IV	+1.598	<.001	9	view →
LUAD	Male	III,IV	+1.413	<.001	9	view →
KIRC	Female	All	+0.567	<.001	9	view →
STAD	Male	II,III,IV	+1.726	<.001	8	view →
LUSC	Female	All	+1.706	<.001	8	view →
BRCA	All	II,III,IV	+0.597	<.001	8	view →
READ	All	All	+1.017	<.001	7	view →
UCEC	All	III,IV	+1.455	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TCF3–HNSC

Open the HNSC breakdown →